Docs slower to drop ‘Black box’ drugs when access to drug reps is restricted
Wednesday, May 23, 2012 - 21:30
in Health & Medicine
After years of reducing their contact with pharmaceutical sales representatives, physicians now risk an unintended consequence: Doctors who rarely meet with pharmaceutical sales representatives — or who do not meet with them — are much slower to drop medicines with the Food and Drug Administration’s “black box” warnings and to adopt first-in-class therapies.